Patents by Inventor Abdul Waseh Basit
Abdul Waseh Basit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240000714Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: June 12, 2023Publication date: January 4, 2024Applicants: Tillotts Pharma AG, University College LondonInventors: Vipul YADAV, Abdul Waseh BASIT, Felipe José OLIVEIRA VARUM, Roberto Carlos BRAVO GONZALÉZ, Esther Maria FURRER
-
Patent number: 11717484Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.Type: GrantFiled: April 26, 2018Date of Patent: August 8, 2023Assignees: Tillotts Pharma AG, University College LondonInventors: Vipul Yadav, Abdul Waseh Basit, Felipe José Oliveira Varum, Roberto Carlos Bravo Gonzaléz, Esther Maria Furrer
-
Patent number: 11534406Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: March 18, 2020Date of Patent: December 27, 2022Assignee: Tillotts Pharma AGInventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 11517534Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: June 2, 2017Date of Patent: December 6, 2022Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20220226251Abstract: This invention relates pharmaceutical compositions comprising a protein as the active ingredient together with one or more dipeptides as stabilising agents, and optionally an enzyme inhibitor. The compositions are particularly useful for administration to the intestinal tract.Type: ApplicationFiled: May 15, 2020Publication date: July 21, 2022Inventors: Abdul Waseh Basit, Vipul Yadav
-
Publication number: 20220202730Abstract: The present invention relates to the therapeutic use of compositions containing 5-aminolevulinic acid for the local treatment of inflammatory bowel disease, including but not restricted to ulcerative colitis and Crohn's disease.Type: ApplicationFiled: April 29, 2020Publication date: June 30, 2022Inventors: Abdul Waseh Basit, Vipul Yadav, Satofumi Kawata, Motoyasu Tomioka, Yasufumi Wada
-
Publication number: 20210267919Abstract: The present invention relates to coated butyrate and butyrate plus DPP-IV inhibitor tablets. It has been discovered that an inner butyrate core, a first layer neutral polymer which can dissolve in the colon, followed by an outer coating of a composition, which dissolves only in the colon, prevents the interaction of butyrate with these compositions.Type: ApplicationFiled: February 28, 2020Publication date: September 2, 2021Applicant: BioKier, Inc.Inventors: Jerzy Ryszard Szewczyk, Nicolas D. Kirkland, Troy A. Bartron, JR., Abdul Waseh Basit
-
Patent number: 10799515Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: October 29, 2013Date of Patent: October 13, 2020Assignee: TILLOTTS PHARMA AGInventors: Felipe Jose Oliveira Varum, Roberto Carlos Bravo Gonzalez, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20200214987Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: March 18, 2020Publication date: July 9, 2020Applicant: Tillotts Pharma AGInventors: Felipe José OLIVEIRA VARUM, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20200170956Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: April 26, 2018Publication date: June 4, 2020Applicants: Tillotts Pharma AG, University College LondonInventors: Vipul YADAV, Abdul Waseh BASIT, Felipe José OLIVEIRA VARUM, Roberto Carlos BRAVO GONZALÉZ, Esther Maria FURRER
-
Patent number: 10668023Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.Type: GrantFiled: March 15, 2019Date of Patent: June 2, 2020Assignee: University College LondonInventors: Abdul Waseh Basit, Valentine Chidi Ibekwe
-
Publication number: 20190254980Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.Type: ApplicationFiled: March 15, 2019Publication date: August 22, 2019Applicant: UNIVERSITY COLLEGE LONDONInventors: Abdul Waseh BASIT, Valentine Chidi Ibekwe
-
Patent number: 10369112Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.Type: GrantFiled: December 7, 2017Date of Patent: August 6, 2019Assignee: UNIVERSITY COLLEGE LONDONInventors: Abdul Waseh Basit, Valentine Chidi Ibekwe
-
Patent number: 10272048Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: September 16, 2016Date of Patent: April 30, 2019Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 10234467Abstract: Apparatus for testing the solubility of a medical dosage form includes a chamber (12) for holding a solvent medium (18), in the preferred embodiment a bicarbonate based buffer system. The apparatus also includes a pH probe (66) which is connectable to a supply of carbon dioxide (32, 34), as well as to a supply of helium (40), the supplies being controlled by a control unit (50). The control unit (50) monitors changes in pH of the solvent medium (18) and, as appropriate, feeds pH increasing and/or pH reducing gas from the supplies (32, 34, 40) into the chamber (12). The control unit (50) is able to maintain a uniform pH during testing or to provide a dynamically adjustable pH during testing, for example to three or more different pH levels in order to test the performance of a drug carrier at different levels of acidity or alkalinity for example, mimicking the conditions of the gastrointestinal tract.Type: GrantFiled: December 28, 2016Date of Patent: March 19, 2019Assignee: UCL Business PLCInventors: Hamid Ali Merchant, John Andrew Frost, Abdul Waseh Basit
-
Patent number: 10226430Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralized polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: GrantFiled: April 29, 2013Date of Patent: March 12, 2019Assignee: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Patent number: 9993435Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.Type: GrantFiled: April 1, 2015Date of Patent: June 12, 2018Assignee: UNIVERSITY COLLEGE LONDONInventors: Abdul Waseh Basit, Valentine Chidi Ibekwe
-
Publication number: 20180098944Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.Type: ApplicationFiled: December 7, 2017Publication date: April 12, 2018Applicant: UNIVERSITY COLLEGE LONDONInventors: Abdul Waseh BASIT, Valentine Chidi IBEKWE
-
Publication number: 20170266117Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: June 2, 2017Publication date: September 21, 2017Applicant: Tillotts Phharma AGInventors: Felipe Josè OLIVEIRA VARUM, Roberto Carlos BRAVO GONZÁLEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE
-
Publication number: 20170108519Abstract: Apparatus for testing the solubility of a medical dosage form includes a chamber (12) for holding a solvent medium (18), in the preferred embodiment a bicarbonate based buffer system. The apparatus also includes a pH probe (66) which is connectable to a supply of carbon dioxide (32, 34), as well as to a supply of helium (40), the supplies being controlled by a control unit (50). The control unit (50) monitors changes in pH of the solvent medium (18) and, as appropriate, feeds pH increasing and/or pH reducing gas from the supplies (32, 34, 40) into the chamber (12). The control unit (50) is able to maintain a uniform pH during testing or to provide a dynamically adjustable pH during testing, for example to three or more different pH levels in order to test the performance of a drug carrier at different levels of acidity or alkalinity for example, mimicking the conditions of the gastrointestinal tract.Type: ApplicationFiled: December 28, 2016Publication date: April 20, 2017Inventors: Hamid Ali Merchant, John Andrew Frost, Abdul Waseh Basit